Loading...

CRSP CRISPR THERAPEUTICS AG Capital Structure Changes 8-K Filing

CRSP

CRSP

CRISPR THERAPEUTICS AG

(CRSP)

2026 8-K

Financial Results Announced

Funding Announcement

Fundraising Announcement

Financial Results Announced

Clinical Updates Released

Financial Results Release

Share Offering Planned

Financial Statements

Product Expansion

Elections and Re-elections

Financial Statements

Management Change

Financial Results

Financial Results

Financial Results Announcement

Approval of Amendment to CR...

Appointment of Julianne Bru...

Financial Results Announcement

Financial Results Announcement

Investment Agreement

Resignation of CMO

EMA Approval for CASGEVY

Amendment to Collaboration ...

FDA Approval and Milestone ...

Update on Immuno-Oncology P...

Financial Results Announcement

Resignation and Appointment

Financial Results Announcement

Amendment Approval

FDA Acceptance of BLAs for ...

Financial Results Announcement

FDA BLA Submission

Resignation of Director

License Agreement with Vert...

Appointment of New Chief Fi...

Financial Results Announcement

External Links:

On March 16, 2026, CRISPR Therapeutics AG completed a private offering of $600 million in Convertible Senior Notes due 2031, with net proceeds expected to be approximately $585.2 million for general corporate purposes.

AI Assistant

CRISPR THERAPEUTICS AG

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.